Zc3h15, also known as DRG family regulatory protein 1 (DFRP1), is a highly conserved eukaryotic protein associated with active translation machinery [4]. It is involved in multiple cellular processes, interacts with TRAF-2 within the NF-κB pathway, and is ubiquitously expressed in various human tissues [6].

In cancer, Zc3h15 has been found to promote the progression of several tumors. In glioblastoma, it promotes cell proliferation, migration, invasion, and tumorigenesis by activating the EGFR signaling pathway, reducing EGFR ubiquitination, and inhibiting CBL transcription [1]. In gastric cancer, it promotes cell proliferation, migration, and invasion by increasing c-Myc expression through suppressing FBXW7 transcription [2]. In melanoma, its knockdown inhibits cell proliferation, induces cell cycle arrest, and reduces migration, invasion, and tumorigenicity [3]. In hepatocellular carcinoma, elevated Zc3h15 is an independent predictor of poor survival and is associated with tumor invasion and high serum AFP levels [4]. Also, in bone cancer pain murine models, silencing Zc3h15 alleviates pain by inhibiting neuronal oxidative stress and microglial inflammation [5].

In conclusion, Zc3h15 plays significant roles in tumor progression and cancer-related pain. Its functions in promoting cancer cell proliferation, migration, invasion, and tumorigenesis, as well as its impact on cancer-induced pain, are revealed through in vivo studies including mouse models. Understanding Zc3h15 provides potential targets for cancer treatment and pain management.